45,204 Shares in InMode Ltd. $INMD Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new position in InMode Ltd. (NASDAQ:INMD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 45,204 shares of the healthcare company’s stock, valued at approximately $674,000. Y Intercept Hong Kong Ltd owned about 0.07% of InMode as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Blue Trust Inc. lifted its stake in shares of InMode by 93.7% in the 3rd quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock valued at $43,000 after acquiring an additional 1,384 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in InMode in the 3rd quarter worth approximately $52,000. Ritholtz Wealth Management bought a new stake in InMode in the second quarter valued at approximately $151,000. Topline Capital Management LLC purchased a new stake in shares of InMode during the second quarter valued at approximately $160,000. Finally, Inspire Investing LLC purchased a new stake in shares of InMode during the second quarter valued at approximately $185,000. 68.04% of the stock is owned by institutional investors.

InMode Trading Up 5.8%

Shares of NASDAQ INMD opened at $16.62 on Tuesday. The firm has a fifty day simple moving average of $14.56 and a two-hundred day simple moving average of $14.66. The firm has a market capitalization of $1.05 billion, a PE ratio of 7.69 and a beta of 2.19. InMode Ltd. has a 12 month low of $13.14 and a 12 month high of $19.78.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. BTIG Research reaffirmed a “neutral” rating on shares of InMode in a research note on Monday, January 26th. UBS Group cut their price target on shares of InMode from $16.25 to $16.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research note on Friday, October 10th. Wall Street Zen cut InMode from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of InMode in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $16.60.

InMode Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.